linjc16/ctgov huggingface dataset:
Canadian Anticoagulant Percutaneous Coronary Intervention Registry

Study Overview
=================
Brief Summary
-----------------
Advances in mechanical intervention (PCI) and anticoagulation therapy have been the cornerstone of treatment of patients with coronary artery disease. However, the large diversity of approaches to anticoagulation during PCI introduces gaps in knowledge regarding management of cardiac patients. As such, we have initiated a national PCI registry to elucidate anticoagulant choice, dosing strategies, case selection dynamics, and clinical outcomes in the Canadian health care environment.

Official Title
-----------------
Canadian Prospective, Observational Study on the Use of LMWH in the Setting of Percutaneous Coronary Intervention

Conditions
-----------------
Coronary Artery Disease

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 18 or more years of age. Undergoing PCI during treatment with LMWH Provision of written and informed consent Exclusion Criteria: Language, medical, or psychiatric barriers that preclude understanding of informed consent process. Patients in which the site investigator is unable to comply with completion of study documentation following PCI, i.e. patients with planned transfer to another hospital not participating in the registry. Enrollment in a clinical trial involving another anticoagulant agent.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| A<br>Stable/elective PCI patients | |
| B<br>NSTEMI PCI patients | |
| C<br>STEMI PCI patients | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Description of anticoagulant management during PCI and current practices of participating centres will be undertaken |  | in-hospital | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| In-hospital safety outcomes including - major, minor bleeding, requirement for transfusion, death, myocardial infarction (or re-MI), myocardial ischemia requiring urgent revascularization, and major bleeding |  | in-hospital | 
| In-hospital angiographic complications: no reflow, thrombus, occlusion of collateral branches, distal embolism, coronary dissection, acute closure of the culprit vessel |  | in-hospital | 
| PCI-related resources utilization during the study period, including cost of PCI and its treatment (e.g. duration of hospital stay, drug costs, costs related to bleeding such as transfusions) |  | in-hospital | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
coronary artery disease, percutaneous coronary intervention, anticoagulation
S1 Combined With Cisplatin in Treatment of Recurrence/Metastasis of ESCC Open-label Single Center Phase II Clinical Study

Study Overview
=================
Brief Summary
-----------------
Assess the efficacy and safety of S1 combined with cisplatin in treatment of recurrence/metastasis of ESCC

Official Title
-----------------
S1 Combined With Cisplatin in Treatment of Recurrence/Metastasis of ESCC Open-label Single Center Phase II Clinical Study

Conditions
-----------------
Esophageal Squamous Cell Carcinoma

Intervention / Treatment
-----------------
* Drug: S1 combined with cisplatin


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria Joined the study voluntarily and signed informed consent form; Age 18-75 .Presence of at least one index lesion measurable by CT scan or MRI recurrence/metastasis of Esophageal carcinoma or gastroesophageal cancer confirmed by pathology No radiotherapy, chemotherapy or other treatments prior to enrollment PS ECOG 0-1 Life expectancy of more than 3 months ANC≥2×109/L，PLT≥100×109/L，Hb≥90g/L Cr≤1.0×UNL TBIL≤1.25×UNL； ALT/AST≤2.5×UNL，with hepatic metastases ALT/AST≤5.0×UNL；AKP≤2.5×UNL Exclusion Criteria: there is radical cure of the cancer uncontrolled chronic diarrhea and esophageal obstruction Neurological or mental abnormalities Influence of cognitive ability include central nervous system metastases Severe complication(s), e.g.,uncontrolled active infection,myocardial infarction,hypertension,arrhythmia,stenocardia Patient who has metastasis except cured skin basal cell carcinoma and carcinoma in situ of cervix accept other antitumor therapy •Female patients during their pregnant and lactation period, or patients without contraception

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: S1 combined with cisplatin<br> | Drug: S1 combined with cisplatin<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Progression Free Survival |  | from the first cycle of treatment (day one) to two month after the last cycle | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
ESCC
Plan A Birth Control: Randomized Controlled Trial of a Mobile Health Application for Contraception Information

Study Overview
=================
Brief Summary
-----------------
The primary objective of the investigators study was to design a comprehensive and medically accurate contraception counseling mobile health application and evaluate the effects of this contraception counseling application on the contraceptive methods that patients selected and their knowledge of that method.

Conditions
-----------------
Mobile Applications, Contraception, Contraception Behavior

Intervention / Treatment
-----------------
* Other: Mobile Health Application
* Other: Health Educator Counseling


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 18-45 years of age literate in English not at that time using a contraceptive method willing to switch to a new reversible contraceptive method currently sexually active with a male partner and intending to avoid pregnancy for at least one year Exclusion Criteria: women not at risk for unintended pregnancy those who were pregnant seeking pregnancy within the next 12 months history of surgical sterilization or a current partner who had had a vasectomy using long acting reversible birth control method menopausal

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 45 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Health Educator Arm<br>Health Educator for contraception information | Other: Health Educator Counseling<br>* Counseling via health educator<br>|
| Experimental: Mobile Health Application Arm<br>Plan A Birth Control - iPad based application for contraception information | Other: Mobile Health Application<br>* Mobile Health application for contraception information<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Contraception choice | Choice of birth control selected by participant was recorded into electronic database system and compared between the two groups. | Participants were followed for the duration of their clinic visit which was up to one day | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Knowledge of contraception method chosen | A knowledge questionnaire was administered at the end of patient's visit and results were analyzed. | Participants were followed for the duration of their clinic visit which was up to one day |
The Effect of Good Bacteria on Nonalcoholic Fatty Liver Disease in Diabetics

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine whether probiotics, bacteria that may improve liver health, can effectively treat a chronic condition in diabetics that increases fat in the liver.

Detailed Description
-----------------
Nonalcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease in the United States and is also common in diabetics; unfortunately, research on NAFLD has been limited. Safe, inexpensive, and well-tolerated treatments for NAFLD are needed. Recent studies indicate that probiotics help to improve fat breakdown in mice. This study will evaluate the efficacy of probiotic therapy to reduce fat accumulation in the livers of people with NAFLD and diabetes. Participants in this study will be randomly assigned to receive either a probiotic-containing mixture or placebo once daily for 6 months. Blood tests, and magnetic resonance spectroscopy will be used to assess participants at study start and at study completion.

Official Title
-----------------
The Effect of a Probiotic on Hepatic Steatosis

Conditions
-----------------
Fatty Liver, Hepatic Steatosis, Diabetes Mellitus, Liver Diseases

Intervention / Treatment
-----------------
* Drug: Probiotic-containing powder


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Nonalcoholic fatty liver disease Exclusion Criteria: Any cause of liver disease other than hepatic steatosis Diabetes Known or suspected cirrhosis Inability or unwillingness to undergo magnetic resonance procedures Requirement of long-term antibiotic therapy Pregnancy, breast-feeding, or plans to become pregnant

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Probiotic-containing powder|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Probiotics, Bacteria
A Study to Determine Biopsy Rate in Participants With a First Relapse of Breast Cancer

Study Overview
=================
Brief Summary
-----------------
This is a retrospective, and observational cohort study to determine the proportion of breast cancer first relapses, that are biopsied. The duration of the study will be approximately 24 months.

Conditions
-----------------
Breast Cancer

Intervention / Treatment
-----------------
* Other: eBC treated participants


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Participants with histologically confirmed breast cancer treated for early breast cancer (eBC) with first metastatic relapse disease in the period from January 1, 2014 and December 31, 2015 Exclusion Criteria: Not Applicable

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| eBC treated participants<br>Participants with metastatic disease after previously being treated for eBC were observed for 24 months. | Other: eBC treated participants<br>* No intervention administered in this retrospective observational study.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Percentage of biopsied participants with metastatic relapse |  | Approximately up to 24 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Percentage of non-biopsied participants at first relapse according to different reasons for not performing a biopsy of the metastasis |  | Approximately up to 24 months | 
| Percentage of biopsied and non-biopsied participants at first relapse metastatic breast cancer (mBC) for each metastatic site |  | Approximately up to 24 months | 
| Percentage of biopsied participants at first relapse mBC according to each biopsy method |  | Approximately up to 24 months | 
| Percentage of biopsied and non- biopsied participants at first relapse mBC for each molecular profile of primary tumor |  | Approximately up to 24 months | 
| Percentage of biopsied participants at first relapse mBC for each molecular profile of biopsied metastases |  | Approximately up to 24 months | 
| Percentage of biopsied participants at first relapse mBC with same and different molecular profiles between primary tumor and metastasis for each molecular profile |  | Approximately up to 24 months | 
| Time to relapse |  | Approximately up to 24 months | 
| Percentage of participants with type of first line therapy selected for metastatic disease |  | Approximately up to 24 months | 
| Percentage of participants influenced with biopsy in mBC |  | Approximately up to 24 months | 
| Percentage of biopsied and non- biopsied participants at first relapse mBC for each systemic treatment scheme in the adjuvant and in the metastatic setting |  | Approximately up to 24 months |
Brain-Computer Interface and Mind-Body Awareness Training

Study Overview
=================
Brief Summary
-----------------
Mind-Body Awareness Training (MBAT), in the forms of various yoga and meditative practices, has become increasingly prevalent due to an increase in awareness of the potential health benefits, and improvements in concentration that this training can provide to practitioners. In the present study, we investigate the role of Mind-Body Awareness Training (MBAT) in the initial learning of a sensorimotor (SMR) based Brain-Computer Interface (BCI). The PI's hypothesis is that MBAT will improve performance in SMR based BCI.

Detailed Description
-----------------
In this protocol, we will test the PI's hypothesis that MBAT including yoga will improve the ability for subjects to concentrate on control the SMR thus improving the performance of BCI. Subjects will be recruited for short term MBAT and then undergo BCI training. The performance of subjects with MBAT will be compared with those without MBAT to test the hypothesis. Procedures involved include 6 weeks yoga classes with at least 3 classes per week, and a EEG brain noninvasive brain computer interface study.

Official Title
-----------------
Brain-Computer Interface and Mind-Body Awareness Training

Conditions
-----------------
Healthy Subjects

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 18-64 years old healthy subjects Exclusion Criteria: History of traumatic brain injury/brain lesion, history of neurological deficit or neurodegenerative disorder, or history of epileptic seizures.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 64 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Healthy Subjects<br>Healthy Subjects | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Performance over BCI sessions | During the course of the study over 5-10 weeks, we will quantitatively examine three main components of data: the proportion of subjects that achieve a pre-determined threshold of one-dimensional BCI competency as a time to event analysis, how subjects performed on average in each metric (accuracy, speed, etc.) over the course of the study (5-10 weeks), and subject learning over time during the course of study (5-10 weeks). | one to three months |
Gut Derived Hormones, Body Composition and Metabolism in Prader-Willi Syndrome

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to investigate the effects of a GLP-1 agonist on satiety hormones in patients with Prader-Willi Syndrome (genetic defect causing obesity).

Detailed Description
-----------------
Prader-Willi Syndrome (PWS) is the most frequent known genetic disorder of obesity. Hyperphagia is the main barrier to independent living in adults with PWS, and hitherto behavioural restraints and environmental modification are the only effective management measure. The emerging costs for professional care are immense. Thus, there is an urgent need for treatment which reduce appetite and food intake in this patient group. Agonists of the gut derived hormone GLP-1 which reduces food intake and causes weight loss due to slowed gastric emptying and through direct central effects. The aim of this pilot drug trial is to analyse the effect of a GLP-1 agonist on appetite regulating hormones, insulin secretion and energy expenditure before and after a meal.

Official Title
-----------------
Contribution of a GLP-1 Agonist to Appetite Regulation, Metabolism and Body Composition in Subjects With Prader-Willi Syndrome.

Conditions
-----------------
Prader-Willi Syndrome

Intervention / Treatment
-----------------
* Drug: Exenatide


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: see below Exclusion Criteria: Diabetes mellitus, acute infections

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 45 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: PWS<br> | Drug: Exenatide<br>* 10ug Exenatide single s.c. injection<br>|
| Other: Controls<br> | Drug: Exenatide<br>* 10ug Exenatide single s.c. injection<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| satiety hormones |  | 1 day | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| appetite (visual analogue scale) insulin secretion |  | 1 day |
Differences in Brain Activity in the Application of Upper Limb Exercise Tasks Through Virtual Reality

Study Overview
=================
Brief Summary
-----------------
This study aims to find out the difference in brain activity when performing upper limb exercise tasks through virtual reality-based MOTOCOG equipment for chronic stroke patients.

Detailed Description
-----------------
This study aims to find out the difference in brain activity when performing upper limb exercise tasks through virtual reality-based MOTOCOG equipment for chronic stroke patients. All participants will participate in tasks for upper limb exercise conducted for 26 minutes.

Official Title
-----------------
Differences in Brain Activity in the Application of Upper Limb Exercise Tasks Through Virtual Reality in Chronic Stroke Patients

Conditions
-----------------
Stroke

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients aged 19 to 80 years FMA Upper scores more than 25 and less than 58 Patients whose lesions do not include stimulation regions Patients with stroke with more than 6 months of onset K-MMSE scores more than 24 patients who can Grasp & release Exclusion Criteria: Difficult to communicate due to severe language impairment. Accompanied by an existing serious neurogenic disease Existing significant psychiatric disorders such as major schizophrenia, bipolar disorder

Ages Eligible for Study
-----------------
Minimum Age: 19 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Cross-sectional study, no arm<br>Experimental: Training with the virtual reality program (MOTOCOG) Training consists of 26 minutes task-specific training. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Fugl-Meyer Assessment Upper Extremity | Measurement of motor function of upper and lower extremities. The minimum and maximum values are 0 and 66, and higher scores mean a better outcome. | Baseline | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Grip and Tip pinch strength test | The test is to measure the maximum isometric strength of hand, forearm, and finger muscles. | Baseline | 
| Box & Block Test | The test is used to measure the gross manual dexterity of a patient, or of a person using an upper limb prosthetic device. | Baseline | 
| 9-hole pegboard test | The test is a standardized, quantitative assessment used to measure finger dexterity of a patient. | Baseline | 
| Jebsen-Taylor Hand Function test | This test is a standardized and objective measure of fine and gross motor hand function using simulated activities of daily living (ADL). | Baseline |